Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 update for VYVGART/Efgartigimod Alfa (FcRn Blocker) in Myositis. The expected timing is based on the latest available company guidance and may change.
08/06/26:- ALKIVIA Phase 2/3 myositis topline results expected Q3 2026. 08/17/26:- ALKIVIA Ph3 topline positive in autoimmune myositis. Detailed results to be presented; timing TBA.
Verification
Confirm timing and program details against the company announcement or filing.